June 19, 2021                                                           View this email in your browser

ALDA Returns to In-Person Events
This October


ALDA is excited to return to in-person events starting this fall at our Senior Management Conference, taking place October 3-5 at the Montage at Laguna BeachRegistration information and more program details will be shared in early July; be sure to add these dates to your calendar now! A brief overview of the event:

ALDA Fall Senior Management Conference
The Montage at Laguna Beach
October 3-5, 2021

The topic for this event will be proteomics; the newest developments in this space, how companies are capitalizing on these opportunities, and the implications for ALDA member companies. Attendees will experience the top-tier sessions and networking you have come to expect at an ALDA event, including:
  • Opening dinner speaker: Chris Voss, a former international hostage negotiator for the FBI and best-selling author of Never Split the Difference: Negotiating As If Your Life Depended On It.
  • Proteomics sessions will kick off on Monday with a session presented by Puneet Souda with SVB Leerink, who will provide a strategic overview of the current state of proteomics; how we got here and where we’re going.
  • The rest of Monday’s proteomics-focused sessions will include an executive roundtable from up-and-coming companies in this space, sessions focused on the utilization of AI and other technologies within this field, and the implications for personalized medicine, drug discovery, diagnostics & more.
  • We will close with a dynamic keynote speaker on Tuesday morning, October 5.
Watch your inbox for more information on speakers and registration. We look forward to seeing you in October!

                                   Chris Voss                                   Puneet Souda
ALDA Welcomes Ten New Members

Calibre Scientific, located in Holland, Ohio is a diversified global developer, manufacturer, and distributor of consumables to biopharmaceutical companies, universities, hospitals, and reference labs worldwide.

The official rep to ALDA is Ben Travis, CEO and the alternate is Mike Brownleader, CSO.


Fortis Life Sciences is located Auburndale, Massachusetts. They offer reagents and tools for research, diagnostics and therapeutics customers globally.

Brian Kim, CEO, will be the official representative to ALDA and Ken Yoon, COO will be the alternate.

Gener8 provides complete lifecycle engineering and manufacturing solutions for highly complex instruments and consumables within the Biotech and Medical markets. Their extensive capabilities and expert staff afford clients unique advantages, including solving “unsolvable” problems, breakthrough technologies, acceleration to market, increased ROI, and impressive capital raises. They are based in Sunnyvale, California.

Gener8's official rep is Jerry Jurkiewicz, CEO and the alternate is David Stelter, VP, Sales and Marketing.

Labconco, based in Kansas City, Missouri, manufactures lab equipment specializing in ventilation enclosures (ie: chemical fume hoods and biological safety cabinets), glassware washers, freeze dryers, evaporators, glove boxes and specialized forensic enclosures.

Laura Perin, CEO is the official representative to ALDA and Jeff Stanton, President, is the alternate.

Nicoya Lifesciences, located in Ontario, Canada, develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions. Alto, the world’s first digital high-throughput benchtop SPR instrument, is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses.
The official rep is Ryan Denomme, CEO and the alternate rep is David Panzarella, CCO,

Phase Genomics, Inc. is based in Seattle, Washington and leverages ultra-long-range sequencing, a technology based on the capture of chromosome conformation, to develop advanced diagnostic and discovery tools. The company sells reagent kits as well as lab and computational services to enable improved genome assembly and phasing, microbiome discovery, and the ability to detect chromosomal aberrations in clinical settings.

Ivan Liachko, CEO, will be the official representative to ALDA, and Kayla Young, COO will be the alternate. 

Refeyn Ltd., located in Oxford, United Kingdom, produces a disruptive new generation of analytical instruments that measures the mass of individual molecules directly in solution.  Mass photometry transforms the ability to characterize the composition, structure and dynamics of biomolecules.

Anthony Fernandez, CEO is the official representative and Matthias Langhorst, Chief Product Officer is the alternate rep. 

Resolve Biosciences develops the Molecular Cartography™ platform, a multi-analyte and highly multiplex spatial analysis technology that enables scientists to resolve complex biological challenges in areas such as oncology, neuroscience, and infectious disease. Resolve is located in Monheim am Rhein, Germany with N.A. facility & lab in San Jose, California.

Jason Gammack, CEO, is the official representative and the alternate is Chris Barbazette, CCO.

Scitara, located in Marlborough, Massachusetts is an industry-backed software as a service (SaaS) start-up for the life science sector with the goal of enabling universal data connectivity in scientific laboratories.

Ajit Nagral, CEO, is the official rep and Geoff Gerhardt, CTO is the Alternate.

Vizgen, based in Cambridge, Massachusetts, Vizgen is developing next generation genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease with spatial context. The company's MERSCOPE platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine.

Terry Lo, CEO, is the official rep, and Andrea Jackson, Board Member, is the alternate.
Spring Conference on Pandemics & Infectious Disease Concludes
While we were disappointed that Michael Lewis had to postpone his closing session at the last minute—which we are working to hopefully reschedule—we were very pleased with the rest of our spring conference sessions that were presented to our members for the first three Thursdays in May.
We kicked off our Spring Senior Executives Conference with an industry CEO Roundtable featuring a distinguished panel of prominent industry CEOs who discussed the impact that the COVID pandemic has had on our industry and their organizations, and what it means for the ALDA community. 
On May 13, we heard from Dr. Pardis Sabeti of the Broad Institute and Harvard School of Public Health who spoke about the hunt for the next pandemic and the pandemic response in the modern age, with an eye towards planning for the future and what role we can all play moving forward.
And on May 20, we had two outstanding presentations from Dr. Phil Dormitzer (Pfizer) who spoke about the future of vaccine development and how Pfizer was a leader in the development of the COVID-19 vaccine, and Dr. Penny Heaton (Bill & Melinda Gates Medical Research Institute) who spoke about the future of vaccine development and their efforts with infectious diseases such as tuberculosis and malaria.
Thank you to the well over 100 ALDA member executives who attended at least one of these sessions! We enjoyed reaching so many of you through this virtual format and look forward to continuing to expand on these offerings while returning to in-person events.
ALDA Website
ALDA Website
    Thank You to
    our Members

Thank you to the ALDA member community for your support over the past year. The video below contains some highlights of what we have been able to accomplish collectively as an association. We went into our membership/fiscal year with a lot of uncertainty as we had to press pause on our in-person events. Instead of taking a step backwards, we were able to recognize over 90% member retention and saw overall net membership growth of 7%. We now head into our next fiscal year stronger than ever, armed with a new strategic plan and targeting an October return to our
in-person meetings.

We couldn't have done this without our outstanding leadership and members (both returning and new). We look forward to continuing to expand our value proposition and building the future of ALDA.

Membership Dues Renewals Sent Out

We greatly appreciate and value your membership in ALDA; as we continue to prove, we are stronger together. Membership in this association has never been more critical or vital. We look forward to continuing to grow and evolve with you. The future of ALDA is very bright, and we will continue to advance as an association
and industry. 

Membership dues renewals have been sent to all ALDA members.

Payments received by July 15 receive a 2% discount. Please reach out if you have
any questions.
Events Calendar

Jun 24
European & Global Industry Economic Outlook Webinar

Oct 3-5
2021 Senior Management Conference
Laguna Beach, California

May 1-3
2022 Spring Senior Executives Conference
Boston, Massachusetts

European & Global Industry Economic Outlook Webinar on June 24
In partnership with our friends at EUROM II—a European association that brings together national associations representing the analytical and laboratory tools & equipment industry in the EU—we invite you to a session focused on the industry economic outlook for 2021 & 2022. This 60-minute session will include speakers from Deutsche Bank, SDI, and representatives of national associations in Germany, France & the UK. 

European & Global Industry Economic Outlook
Thursday, June 24
10:30 AM Eastern US Time

• Economic Outlook in Europe
Presented by Eric Heymann, Senior Economist at Deutsche Bank
• Overview of North American & Global Market
Presented by Mike Tice, Senior Vice President with SDI/Instrumental Business Outlook (IBO)
• Market developments in UK, Germany and France
Presented by GAMBICA, Fabrilabo, and SPECTARIS

Register HERE!  We look forward to seeing you on June 24!
ALDA Collaborative--"Return to the Office"--in July
With so many member companies expanding their return to office initiatives and contemplating the future of work, ALDA will convene our collaborative to again offer an opportunity for members to hear from their colleagues. What steps have they already taken? What’s working, and what hasn’t? How are they looking at the future of work for their organizations? An exact date and time will be shared the week of June 28, along with registration information. We look forward to seeing your companies there.
Industry Assessment: ALDA’s Market Up 21% YOY in Q1

ALDA’s latest Industry Market Assessment report is now available, focused on Q1 2021. Total demand in the industry soared 21%, exceeding $14 billion for the second consecutive quarter. The huge growth is partly due to the comparison with 2020, when first quarter demand fell 1.8% year-over-year. Life science (LS) products slightly edged out chromatography, mass spectrometry & automation (CMSA) to be the fastest growing segment. CMSA’s strong quarter was driven by resurgent chromatography and mass spec sales. Analytical chemicals grew in the high teens, while the spectroscopy and materials analysis (SMA) market climbed 15.6%.

Asia-Pacific demand experienced the most year-over-year growth, driven by organic sales across all customer types and the comparison with 2020, when China was in lockdown as the early epicenter of COVID-19. Europe also saw better than average growth in the quarter, boosted by currency effects of 6%-7% against the dollar, on top of strong pharma sales and returning demand in academic labs. North America grew in the high teens as demand picked up across most end-markets.

Please note:
Updated market data from the most recent edition of the Global Assessment Report has now been incorporated into the ALDA data, resulting in some resizing of markets, but no changes in definitions. The year 2020 presented significant challenges to our market estimates and models; most product areas have seen adjustments based on the more comprehensive research presented in the Global Assessment Report. Please reach out if you need more information; we regret any inconvenience caused by these adjustments.

The Industry Market Assessment report, prepared quarterly by Strategic Directions International (“SDi”) for members of ALDA, is based on public reports and SDi’s proprietary research. The ALDA market, of about 50 technology segments grouped into 15 reported segments most important to ALDA’s membership, is estimated to be 75-80% of total global industry revenues.
To access the report, log in to the member resources section of the website or email
Copyright © 2021 Analytical, Life Science & Diagnostics Association (ALDA), All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp